VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
NCT ID: NCT07104383
Last Updated: 2025-11-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
1100 participants
INTERVENTIONAL
2025-06-23
2027-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo Assignment
VK2735 Placebo Comparator Once Weekly
VK2735
VK2735 is a peptide GLP-1 and GIP dual agonist administered Once Weekly
Active Assignment (Dose #1)
VK2735 7.5mg Once Weekly
VK2735
VK2735 is a peptide GLP-1 and GIP dual agonist administered Once Weekly
Active Assignment (Dose #2)
VK2735 12.5mg Once Weekly
VK2735
VK2735 is a peptide GLP-1 and GIP dual agonist administered Once Weekly
Active Assignment (Dose #3)
VK2735 17.5mg Once Weekly
VK2735
VK2735 is a peptide GLP-1 and GIP dual agonist administered Once Weekly
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VK2735
VK2735 is a peptide GLP-1 and GIP dual agonist administered Once Weekly
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Body mass index (BMI) ≥27 kg/m2
3. Have Type 2 Diabetes Mellitus according to the American Diabetes Association with HbA1c ≥ 7% to ≤ 11% at screening, on stable therapy for the last 3 months prior to Screening. Type 2 diabetes mellitus may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling), EXCEPT for amylin analogues or dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1R agonists or dual GLP-1/ glucose-dependent insulinotropic polypeptide (GIP) receptor agonists
Exclusion Criteria
2. Self-reported body weight change of 5% or more within 3 months of screening
3. Have a prior or planned surgical treatment for obesity (except for liposuction or abdominoplasty if performed \>1 year prior to screening)
4. Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as mucosal ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line)
5. Have Type 1 diabetes mellitus, history of ketoacidosis or hyperosmolar state/coma or any other types of diabetes except Type 2 diabetes mellitus (T2DM)
6. Have had 1 or more episodes of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 6 months of screening
• Note: Severe hypoglycemia episodes should be considered when severe cognitive impairment requiring the assistance of another person occurs and the administration of carbohydrate, glucagon, or other resuscitative actions are required. Blood glucose (BG) measurements may not be available during such an event, but neurological recovery attributable to the restoration of BG to normal is considered sufficient evidence that the event was induced by a low BG concentration. If BG measurements are available, the levels associated with severe hypoglycemia are BG \< 54 mg/dL
7. Have at least 2 confirmed fasting self-monitoring blood glucose (SMBG) values \> 270 mg/dL (on 2 non-consecutive days) within 4 weeks prior to randomization
8. Have proliferative diabetic retinopathy OR diabetic macular edema OR non-proliferative diabetic retinopathy that requires acute treatment
9. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)
10. History of acute or chronic pancreatitis
11. Thyroid disease that is not controlled (Thyroid stimulating hormone (TSH) outside normal range by central lab at screening; one repetition during screening is allowed). Participants with previous history of partial/total thyroidectomy or hypothyroidism may be included, provided their hormone replacement dose has been stable for 3 months prior to screening
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Viking Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Viking Clinical Site #2037
Birmingham, Alabama, United States
Viking Clinical Site #2064
Birmingham, Alabama, United States
Viking Clinical Site #2128
Huntsville, Alabama, United States
Viking Clinical Site #2081
Mobile, Alabama, United States
Viking Clinical Site #2005
Chandler, Arizona, United States
Viking Clinical Site #2017
Flagstaff, Arizona, United States
Viking Clinical Site #2018
Peoria, Arizona, United States
Viking Clinical Site #2135
Scottsdale, Arizona, United States
Viking Clinical Site #2019
Tucson, Arizona, United States
Viking Clinical Site #2036
Little Rock, Arkansas, United States
Viking Clinical Site #2071
Chula Vista, California, United States
Viking Clinical Site #2070
Escondido, California, United States
Viking Clinical Site #2054
Huntington Park, California, United States
Viking Clinical Site #2014
Lake Forest, California, United States
Viking Clinical Site #2129
Lemon Grove, California, United States
Viking Clinical Site #2051
Lincoln, California, United States
Viking Clinical Site #2050
Long Beach, California, United States
Viking Clinical Site #2055
Los Angeles, California, United States
Viking Clinical Site #2078
Manteca, California, United States
Viking Clinical Site #2053
Montclair, California, United States
Viking Clinical Site #2068
Panorama City, California, United States
Viking Clinical Site #2132
Rolling Hills Estates, California, United States
Viking Clinical Site #2131
San Diego, California, United States
Viking Clinical Site #2052
Spring Valley, California, United States
Viking Clinical Site #2109
Tustin, California, United States
Viking Clinical Site #2067
Van Nuys, California, United States
Viking Clinical Site #2079
Walnut Creek, California, United States
Viking Clinical Site #2119
Denver, Colorado, United States
Viking Clinical Site #2123
Washington D.C., District of Columbia, United States
Viking Clinical Site #2013
Clearwater, Florida, United States
Viking Clinical Site #2121
Clearwater, Florida, United States
Viking Clinical Site #2003
Cooper City, Florida, United States
Viking Clinical Site #2112
DeLand, Florida, United States
Viking Clinical Site #2107
Delray Beach, Florida, United States
Viking Clinical Site #2083
Fort Myers, Florida, United States
Viking Clinical Site #2058
Jacksonville, Florida, United States
Viking Clinical Site #2076
Lakeland, Florida, United States
Viking Clinical Site #2060
Lakewood Rch, Florida, United States
Viking Clinical Site #2117
Miami, Florida, United States
Viking Clinical Site #2012
Ocoee, Florida, United States
Viking Clinical Site #2056
Palmetto Bay, Florida, United States
Viking Clinical Site #2011
Port Orange, Florida, United States
Viking Clinical Site #2057
West Palm Beach, Florida, United States
Viking Clinical Site #2116
Atlanta, Georgia, United States
Viking Clinical Site #2030
Columbus, Georgia, United States
Viking Clinical Site #2120
Rincon, Georgia, United States
Viking Clinical Site #2093
Savannah, Georgia, United States
Viking Clinical Site #2025
Woodstock, Georgia, United States
Viking Clinical Site #2062
Honolulu, Hawaii, United States
Viking Clinical Site #2080
Meridian, Idaho, United States
Viking Clinical Site #2006
Chicago, Illinois, United States
Viking Clinical Site #2127
Valparaiso, Indiana, United States
Viking Clinical Site #2022
West Des Moines, Iowa, United States
Viking Clinical Site #2099
Wichita, Kansas, United States
Viking Clinical Site #2069
Lexington, Kentucky, United States
Viking Clinical Site #2040
Lexington, Kentucky, United States
Viking Clinical Site #2009
Louisville, Kentucky, United States
Viking Clinical Site #2118
Baton Rouge, Louisiana, United States
Viking Clinical Site #2139
Baton Rouge, Louisiana, United States
Viking Clinical Site #2106
Lafayette, Louisiana, United States
Viking Clinical Site #2020
Metairie, Louisiana, United States
Viking Clinical Site #2087
Monroe, Louisiana, United States
Viking Clinical Site #2094
Chevy Chase, Maryland, United States
Viking Clinical Site #2066
Rockville, Maryland, United States
Viking Clinical Site #2001
Methuen, Massachusetts, United States
Viking Clinical Site #2100
Lansing, Michigan, United States
Viking Clinical Site #2038
Ypsilanti, Michigan, United States
Viking Clinical Site #2140
Gulfport, Mississippi, United States
Viking Clinical Site #2031
City of Saint Peters, Missouri, United States
Viking Clinical Site #2016
Kansas City, Missouri, United States
Viking Clinical Site #2125
Springfield, Missouri, United States
Viking Clinical Site #2108
St Louis, Missouri, United States
Viking Clinical Site #2010
Butte, Montana, United States
Viking Clinical Site #2075
Omaha, Nebraska, United States
Viking Clinical Site #2035
Las Vegas, Nevada, United States
Viking Clinical Site #2034
Reno, Nevada, United States
Viking Clinical Site #2065
Lebanon, New Hampshire, United States
Viking Clinical Site #2095
Marlton, New Jersey, United States
Viking Clinical Site #2029
Albuquerque, New Mexico, United States
Viking Clinical Site #2088
Albany, New York, United States
Viking Clinical Site #2042
East Syracuse, New York, United States
Viking Clinical Site #2096
Hartsdale, New York, United States
Viking Clinical Site #2133
New York, New York, United States
Viking Clinical Site #2021
The Bronx, New York, United States
Viking Clinical Site #2032
Westfield, New York, United States
Viking Clinical Site #2141
Charlotte, North Carolina, United States
Viking Clinical Site #2101
Fayetteville, North Carolina, United States
Viking Clinical Site #2026
Greensboro, North Carolina, United States
Viking Clinical Site #2110
Morehead City, North Carolina, United States
Viking Clinical Site #2061
Morehead City, North Carolina, United States
Viking Clinical Site #2115
Winston-Salem, North Carolina, United States
Viking Clinical Site #2027
Fargo, North Dakota, United States
Viking Clinical Site #2043
Cincinnati, Ohio, United States
Viking Clinical Site #2074
Cincinnati, Ohio, United States
Viking Clinical Site #2044
Cleveland, Ohio, United States
Viking Clinical Site #2089
Columbus, Ohio, United States
Viking Clinical Site #2113
Norman, Oklahoma, United States
Viking Clinical Site #2137
Tulsa, Oklahoma, United States
Viking Clinical Site #2097
Portland, Oregon, United States
Viking Clinical Site #2126
Portland, Oregon, United States
Viking Clinical Site #2045
East Greenwich, Rhode Island, United States
Viking Clinical Site #2028
Greenville, South Carolina, United States
Viking Clinical Site #2134
Myrtle Beach, South Carolina, United States
Viking Clinical Site #2023
North Charleston, South Carolina, United States
Viking Clinical Site #2004
Knoxville, Tennessee, United States
Viking Clinical Site #2008
Nashville, Tennessee, United States
Viking Clinical Site #2047
Abilene, Texas, United States
Viking Clinical Site #2063
Austin, Texas, United States
Viking Clinical Site #2007
Austin, Texas, United States
Viking Clinical Site #2091
Bellaire, Texas, United States
Viking Clinical Site #2124
Brownsville, Texas, United States
Viking Clinical Site #2049
Dallas, Texas, United States
Viking Clinical Site #2048
Dallas, Texas, United States
Viking Clinical Site #2111
Frisco, Texas, United States
Viking Clinical Site #2046
Houston, Texas, United States
Viking Clinical Site #2077
Lampasas, Texas, United States
Viking Clinical Site #2143
San Antonio, Texas, United States
Viking Clinical Site #2085
San Antonio, Texas, United States
Viking Clinical Site #2015
San Antonio, Texas, United States
Viking Clinical Site #2102
Seabrook, Texas, United States
Viking Clinical Site #2002
Ogden, Utah, United States
Viking Clinical Site #2092
Salt Lake City, Utah, United States
Viking Clinical Site #2039
Sandy City, Utah, United States
Viking Clinical Site #2024
St. George, Utah, United States
Viking Clinical Site #2098
Arlington, Virginia, United States
Viking Clinical Site #2082
Suffolk, Virginia, United States
Viking Clinical Site #2072
Renton, Washington, United States
Viking Clinical Site #2041
Spokane, Washington, United States
Viking Clinical Site #2130
Mayagüez, , Puerto Rico
Viking Clinical Site #2086
San Juan, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VK2735-302
Identifier Type: -
Identifier Source: org_study_id